Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
about
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseasesEvidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia[Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescription data].The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia.Dutasteride for the treatment of prostate-related conditions.Role of 5α-reductase inhibitors in benign prostatic diseases.Dutasteride for the treatment of benign prostatic hyperplasia.Association of Suicidality and Depression With 5α-Reductase Inhibitors.Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis.Lower urinary tract symptoms in men.Maximum Urine Flow Rate of Less than 15ml/Sec Increasing Risk of Urine Retention and Prostate Surgery among Patients with Alpha-1 Blockers: A 10-Year Follow Up Study.Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.5-alpha-reductase inhibitor therapy postpones urine retention and prostate surgery in patients with prostate enlargement and a maximum uroflow rate of less than 15 ml/sec.The prostatic urethral angle can predict the response to alpha adrenoceptor antagonist monotherapy for treating nocturia in men with lower urinary tract symptom: A multicenter study.Treatment assignment guesses by study participants in a double-blind dose escalation clinical trial of saw palmetto.Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implicationsTrends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.Investigational therapies targeted to the treatment of benign prostatic hyperplasia.Medical management of lower urinary tract symptoms in men with benign prostatic enlargement.Current pharmacological treatment options for male lower urinary tract symptoms.The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP.Hormonal manipulation of lower urinary tract symptoms secondary to benign prostatic obstruction.Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder.Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function.A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia.5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis.Pharmacologic Therapy in Men's Health: Hypogonadism, Erectile Dysfunction, and Benign Prostatic Hyperplasia.Inhibition of androgen induces autophagy in benign prostate epithelial cells.Effect of transurethral split of the prostate using a double-columnar balloon catheter for benign prostatic hyperplasia: A single-center experience of 565 consecutive patients.Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment.Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.5-alpha-reductase inhibitors and the risk of diabetes mellitus: A nationwide population-based study.Hypothesis on Serenoa repens (Bartram) small extract inhibition of prostatic 5α-reductase through an in silico approach on 5β-reductase x-ray structure.Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers.Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.Improved multiparametric MRI discrimination between low-risk prostate cancer and benign tissues in a small cohort of 5α-reductase inhibitor treated individuals as compared with an untreated cohort.Crosstalk between apoptosis and autophagy in prostate epithelial cells under androgen deprivation.The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.Studies on Chromatographic Fingerprint and Fingerprinting Profile-Efficacy Relationship of Saxifraga stolonifera Meerb.Impact of Formulation on the Pharmacokinetics of Dutasteride: Results from Two Phase I Studies.
P2860
Q21285041-24895840-DCED-4505-B1EC-BA4C568103D2Q28077954-113BA681-5C18-4C68-B0E2-6AB821C5F8A4Q31149371-2ED58BBC-493E-4EF8-BF73-12A476DD85C0Q33650768-5FA5B1B5-3AD3-43EE-9C1E-90149B6C7A29Q34252953-20286B28-F963-4DAC-9B82-6E0CD133C84CQ34254296-590E2151-9841-4F4E-B539-9B6D207AF77CQ34349726-ED009AE7-DEFF-46B1-A140-96046EF66FB5Q34553657-04B08F1D-B947-47BE-BCB9-6012B8FDB8A0Q35087049-F5D2D80D-0FD7-450E-B113-AD4FB5418AF0Q35225398-BEF99C50-3FDE-468F-B180-07DA95286D86Q36101355-AACB0FE2-69C7-4AEE-AA3C-623762425F01Q36118714-C251B55D-915C-43BB-836B-CBE2ED2AA24AQ36342157-B67AC3A5-B8F5-4152-88A6-61E95868F755Q36680616-8721B907-74FB-4306-8252-5F8352FAC93FQ37523940-20713ABE-12D9-40C8-82DD-FBB2840C4271Q37639218-50D6F0ED-CCCC-43B6-9A9B-B96AA0CB14F4Q37656444-F4E3161F-A9BC-4611-8CCF-B19C48CC189DQ38073830-8BA58315-5D9D-411B-97A5-18EA86B46EB3Q38098896-9173F8EC-435A-4E23-AC37-21CFD61C94CAQ38103891-AF2E7956-35E8-43CA-840F-78DB6FA94579Q38136528-4BF73644-6E56-4F4E-9C96-AE170FF307CBQ38205422-7FFDBB39-FBE5-470E-AD80-9066FCAB601FQ38230461-EB511427-B836-4669-86B1-1A83162F958BQ38239520-F07385F7-EABE-4131-8AEE-037A7C4E44F7Q38485721-FD04EBB8-20E4-4D28-BD96-FC0565DA3125Q38795176-08152175-CF46-460B-8B84-ECFE0289726CQ38846845-164634C6-A8DE-4CB2-A094-9DAE8D64DBFBQ39131649-2B0A2BA8-6429-478A-A463-0A29AFC1A852Q39282111-48264C55-6046-4BD4-90ED-493697B55ACAQ40045955-BD01A1A3-2969-4EDD-96A3-C580C63BCFAAQ41092813-6EC38CEA-8BB8-4C71-A451-C7904E4DBBB4Q41338878-DB315ADC-094F-41CB-BAE0-70E7339075C9Q42198644-584565B5-6788-493D-9FE8-28375833A99FQ44768432-B8447A0E-CBF7-4F0E-8235-B4B71C51EBBBQ45339114-2E38CBF6-24B3-475C-96BA-D089D3590680Q47983820-1818DFBF-85A0-4878-840F-3586A80EAE66Q49884490-FB7863A1-42D4-4D14-B345-AB73BD185C6EQ51287907-F8B0554F-C6CF-418E-A2F6-5269F2F676A1Q51592487-ADE9AC13-43A3-4C78-86F1-A7F2370D2794Q51674191-7218E255-5A80-4F4B-BA0C-4463E592B609
P2860
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Comparison of dutasteride and ...... onal Comparator Study (EPICS).
@en
Comparison of dutasteride and ...... International Comparator Study
@nl
type
label
Comparison of dutasteride and ...... onal Comparator Study (EPICS).
@en
Comparison of dutasteride and ...... International Comparator Study
@nl
prefLabel
Comparison of dutasteride and ...... onal Comparator Study (EPICS).
@en
Comparison of dutasteride and ...... International Comparator Study
@nl
P2093
P2860
P1433
P1476
Comparison of dutasteride and ...... onal Comparator Study (EPICS).
@en
P2093
Betsy Morrill
J Curtis Nickel
Peter Gilling
Roger S Rittmaster
Teuvo L Tammela
Timothy H Wilson
P2860
P304
P356
10.1111/J.1464-410X.2011.10195.X
P577
2011-06-01T00:00:00Z